Hormonal determinants of erectile dysfunction and lower urinary tract symptoms in middle-aged and elderly men with prediabetes

References

• Saad F, Gooren LJ. The Role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes 2011;pii:471584
   Google Scholar
• Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal. Results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589–98
   PubMed Web of Science ®Google Scholar
• Yassin AA, Saad F, Gooren LJ. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia 2008;40:259–64
   PubMed Web of Science ®Google Scholar
• Maggio M, Lauretani F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 2007;167:2249–54
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37:S81–90
   PubMed Web of Science ®Google Scholar
• Bergman M. Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine 2013;43:504–13
   PubMed Web of Science ®Google Scholar
• Cho NH, Whiting D, Guariguata L. IDF diabetes atlas. 6th ed. Belgium: International Diabetes Federation; 2013:39–49
   Google Scholar
• Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89:5462–68
   PubMed Web of Science ®Google Scholar
• Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911–17
   PubMed Web of Science ®Google Scholar
• Rabijewski M, Papierska L, Piątkiewicz P. Late-onset hypogonadism among old and middle-aged males with prediabetes in Polish population. Aging Male 2015;18:16–21
   PubMed Web of Science ®Google Scholar
• Liu RT, Chung MS, Chuang YC, et al. The presence of overactive bladder wet increased the risk and severity of erectile dysfunction in men with type 2 diabetes. J Sex Med 2012;9:1913–22
   PubMed Web of Science ®Google Scholar
• Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease in men with type 2 diabetes. Diabetes Care 2011;34:1660–75
   PubMed Web of Science ®Google Scholar
• Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1.274 European men suffering from lower urinary tract symptoms. J Urol 2003;169:2257–61
   PubMed Web of Science ®Google Scholar
• Kebapci N, Yenilmez A, Efe B, et al. Bladder dysfunction in type 2 diabetic patients. Neurourol Urodyn 2007;26:814–19
   PubMed Web of Science ®Google Scholar
• Kapoor D, Clarke S, Channer KS, Jones TH. Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. Int J Androl 2007;30:500–7
   PubMed Web of Science ®Google Scholar
• Phe V, Roupret M. Erectile dysfunction and diabetes – a review of current evidence-based medicine and a synthesis of the main available therapies. Diabetes Metab 2012;38:1–13
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Balercia G, et al. Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. J Sex Med 2012;9:1669–80
   PubMed Web of Science ®Google Scholar
• Ho CH, Yu HJ, Wang CY, et al. Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome. PLos One 2013;8:e74173
   PubMed Web of Science ®Google Scholar
• Athyros GV, Ganotakis ES, Mikhailidis DO. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 2005;21:1157–64
   PubMed Web of Science ®Google Scholar
• Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319–26
   PubMed Web of Science ®Google Scholar
• Barry MJ, Fowler FJ Jr, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549–57
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72
   PubMed Web of Science ®Google Scholar
• Colangelo LA, Ouyang P, Liu K, et al. Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: Multi-Ethnic Study of Atherosclerosis. Diabetes Care 2009;32:1049–51
   PubMed Web of Science ®Google Scholar
• Fukui M, Tanaka M, Toda H, et al. Andropausal symptoms in men with Type 2 diabetes. Diabet Med 2012;29:1036–42
   PubMed Web of Science ®Google Scholar
• Yassin AA, Saad F, Gooren LJ. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia 2008;40:259–64
   PubMed Web of Science ®Google Scholar
• Grossmann M, Thomas MC, Panagiotopoulos S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008;93:1834–40
   PubMed Web of Science ®Google Scholar
• Piteous N, Dwyer AA, Decius S, et al. The relative role of gonad sex steroids and gonadotropin-releasing hormone pulse frequency in the regulation of follicle-stimulating hormone secretion in men. J Clin Endocrinol Metab 2008;93:2686–92
   PubMed Web of Science ®Google Scholar
• Maiorino MI, Bellastella G, Esposito K. Diabetes and sexual dysfunction: current perspectives diabetes, metabolic syndrome and obesity. Targets and Therapy 2014;7:95–105
   Google Scholar
• Yoshimura N, Chancellor MB, Andersson KE, Christ GJ. Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int 2005;95:733–8
   PubMed Web of Science ®Google Scholar
• Wang CC, Chancellor MB, Lin JM, et al. Type 2 diabetes but not metabolic syndrome is associated with an increased risk of lower urinary tract symptoms and erectile dysfunction in men aged <45 years. BJU Int 2010;105:1136–40
   PubMed Web of Science ®Google Scholar
• Ferreira FT, Daltoé L, Succi G, et al. Relation between glycemic levels and low tract urinary symptoms in elderly. Aging Male 2015;18:34–7
   PubMed Web of Science ®Google Scholar
• Sarma AV, Burke JP, Jacobson DJ, et al. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling black and white men. Diabetes Care 2008;31:476–82
   PubMed Web of Science ®Google Scholar
• Schatzl G, Madersbacher S, Temml C, et al. Serum androgen levels in men: impact of health status and age. Urology 2003;61:629–33
   PubMed Web of Science ®Google Scholar
• Litman HJ, Bhasin S, O’Leary MP, et al. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey. BJU Int 2007;100:321–6
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Lee JY, O’Neill EA, et al. Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male 2013;16:169–72
   PubMed Web of Science ®Google Scholar
• Kim MK, Zhao C, Kim SD, et al. Relationship of sex hormones and nocturia in lower urinary tract symptoms induced by benign prostatic hyperplasia. Aging Male 2012;15:90–5
   PubMed Web of Science ®Google Scholar
• Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomized controlled study. Aging Male 2011;14:53–8
   PubMed Web of Science ®Google Scholar
• Amano T, Imao T, Takemae K, et al. Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. Aging Male 2010;13:242–6
   PubMed Web of Science ®Google Scholar
• Karazindiyanoğlu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 2008;11:146–9
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Kalinchenko S, Tischova T. Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men – a suggested update. Aging Male 2013;4:143–50
   Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010;7:3495–503
   PubMed Web of Science ®Google Scholar
• Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with “diabesity”: results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol 2014;2014:683515. doi: 10.1155/2014/683515
   PubMed Web of Science ®Google Scholar
• Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828–37
   PubMed Web of Science ®Google Scholar
• Saad F, Yassin A, Almehmadi Y, et al. Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus – a series of case reports. Aging Male. [Epub ahead of print]. doi: 10.3109/13685538.2015.1034687
   Web of Science ®Google Scholar
• Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 2014;11:1567–76
   PubMed Web of Science ®Google Scholar